Adverse effect of antihyperlip and antiarterio drugs, subs

This code signifies a patient experiencing an unintended and harmful reaction to medications prescribed to lower cholesterol or treat hardening of the arteries, during a follow-up visit. These adverse effects can range from mild side effects to severe complications impacting various organ systems. The "subsequent encounter" indicates that the initial treatment for the adverse effect has already begun, and this visit is for ongoing management or evaluation.

Apply this code when a patient presents for follow-up care related to an adverse drug reaction from statins, fibrates, PCSK9 inhibitors, or other lipid-lowering or anti-atherosclerotic agents. This includes visits for monitoring liver function abnormalities, muscle pain (myalgia/rhabdomyolysis), gastrointestinal issues, or other complications that developed after starting these medications. It is used when the patient is no longer in the acute phase of the adverse effect but still requires ongoing management.

• Always sequence this code after the code for the specific adverse effect (e.g., Rhabdomyolysis, Drug-induced hepatitis).
• Ensure documentation clearly states the drug causing the adverse effect and that the encounter is for follow-up care.
• Distinguish from initial encounters (A) or sequela (S) encounters; "D" is specifically for subsequent care.